US Patent

US9308204 — Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Formulation · Assigned to Pfizer Inc · Expires 2030-10-21 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds of Formula (A) and (B) for use in treating diseases, conditions, and/or disorders mediated by sodium-glucose transporter inhibitors.

USPTO Abstract

Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Drugs covered by this patent

Patent Metadata

Patent number
US9308204
Jurisdiction
US
Classification
Formulation
Expires
2030-10-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.